European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

EU mid-market update: Trump adds Middle East tensions to macro picture as trade war keeps volatility high; Novo Nordisk rises ...

Improving the customer onboarding experience in an increasingly competitive and congested financial services industry is vital for both legacy banks and those in fintech serious about growth... Guest ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

Wall Street was mostly lower on Wednesday despite US employment growth picking up last month by more than expected.

A summary of the latest financial news from European markets, including stock performance, unemployment rates, trade surplus, bond yields, and ...

Also in today’s newsletter, Microsoft poaches DeepMind staff behind AI podcasting feature, and FBI agents sue Trump ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...